Community specific data reports for vaccine administration results, updated weekly, and data from the Public Health (DPH) COVID Community Impact Survey to help target approaches.

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season. This table shows the number of CT residents who received an updated 2023-2024 COVID-19 vaccination by week and age group (current age). Only the first dose is counted. CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here. • Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors. • These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US) • People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.

Information about school immunization requirements and data

Access available resources below such as data reports, and Public Health Council presentations.

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

This open dataset shows data on Cambridge residents who have received a COVID-19 vaccine at any location (e.g., mass vaccination site, pharmacy, doctor's office). These data come from the Massachusetts Department of Public Health's weekly report on vaccine doses administered by municipality. The report is released on Thursdays. This open dataset includes data going back several weeks and complements another open dataset called "Cambridge Vaccine Demographics," which shows data for the latest week (https://data.cambridgema.gov/Public-Health/Cambridge-Vaccination-Demographics/66td-u88k)

The Moderna and Pfizer vaccines require two doses administered at least 28 days apart in order to be fully vaccinated. The J&J (Janssen) vaccine requires a single dose in order to be fully vaccinated.

The category "Residents Who Received at Least One Dose" reflects the total number of individuals in the fully and partially vaccinated categories. That is, this category comprises individuals who have received one or both doses of the Moderna/Pfizer vaccine or have received the single dose J&J (Janssen) vaccine.

The category "Fully Vaccinated Residents" comprises individuals who have received both doses of the Moderna/ Pfizer vaccine or the single-dose J&J vaccine.

The category "Partially Vaccinated Residents" comprises individuals who have received only the first dose of the Moderna/Pfizer vaccine.

Source: Weekly COVID-19 Municipality Vaccination Report. Massachusetts releases updated data each Thursday at 5 p.m.

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

Note: As of November 10, 2023, this dataset has been archived. For the current version of this data, please visit: https://health.data.ny.gov/d/gikn-znjh

This dataset reports daily on the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the State to serve as points of distribution.

This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR). County-level vaccination data is based on data reported to NYSIIS and NYC CIR by the providers administering vaccines. Residency is self-reported by the individual being vaccinated. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for county-level statistics. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

Mass Vaccination Vehicle Market Outlook

According to our latest research, the global mass vaccination vehicle market size reached USD 1.62 billion in 2024, reflecting a robust growth trajectory driven by the ongoing need for rapid, accessible immunization solutions. The market is expected to expand at a CAGR of 8.1% from 2025 to 2033, projecting a market value of USD 3.24 billion by 2033. This impressive growth is attributed to the increasing adoption of mobile healthcare infrastructure, government initiatives for public health preparedness, and the persistent threat of infectious diseases worldwide. As per our latest research, the market continues to evolve, fueled by technological advancements and the urgent demand for flexible vaccination delivery systems.

The primary growth factor for the mass vaccination vehicle market stems from the rising emphasis on public health and immunization coverage, particularly in remote and underserved regions. Governments and health organizations are increasingly recognizing the need to bridge the gap in healthcare accessibility, especially in areas where traditional healthcare infrastructure is limited or non-existent. Mass vaccination vehicles provide a versatile and efficient solution, capable of delivering vaccines to populations that might otherwise remain unprotected. The flexibility to deploy these vehicles rapidly during outbreaks or immunization drives has proven invaluable, especially during the COVID-19 pandemic, where quick and widespread vaccine administration was critical. Additionally, the scalability and adaptability of these vehicles make them a preferred choice for both routine and emergency vaccination campaigns.

Another significant driver for the market is the integration of advanced technologies in mass vaccination vehicles, enhancing their operational efficiency and patient management capabilities. Modern vehicles are being equipped with cold chain management systems, electronic health record (EHR) integration, and real-time monitoring tools to ensure vaccine potency and streamline the immunization process. The adoption of electric and hybrid power sources further aligns with the global shift towards sustainable healthcare solutions, reducing the carbon footprint associated with large-scale immunization efforts. These technological enhancements not only improve the efficacy of vaccination campaigns but also increase the appeal of mass vaccination vehicles to government agencies, hospitals, and non-governmental organizations (NGOs) seeking innovative approaches to public health delivery.

The market is also benefiting from increased investments and supportive policy frameworks established by governments and international health bodies. Funding for mobile healthcare infrastructure has surged, particularly in response to lessons learned during the COVID-19 pandemic. Many regions are now prioritizing the establishment of rapid response units capable of addressing future health emergencies, including mass immunization requirements for influenza, measles, and other communicable diseases. Collaborative initiatives between public and private sectors are further accelerating the deployment and customization of mass vaccination vehicles, ensuring they are equipped to handle diverse immunization scenarios. This proactive approach is expected to sustain market growth well into the next decade.

From a regional perspective, North America and Europe currently dominate the mass vaccination vehicle market, accounting for over 60% of the total market share in 2024. This dominance is attributed to well-established healthcare infrastructure, high immunization coverage, and significant investments in mobile healthcare solutions. However, the Asia Pacific region is poised for the fastest growth, with a projected CAGR of 9.3% through 2033, driven by expanding government health initiatives, rising population density, and increasing awareness about the benefits of mobile immunization services. Latin America and the Middle East & Africa are also witnessing steady growth, fueled by international aid programs and efforts to improve healthcare accessibility in remote areas.

Vehicle Type Analysis

The vehicle type segment in the mass vaccination vehicle market is broadly categorized into bus-based, van-based, truck-based, trailer-based, and others. Bus-based mass vaccination vehicles have gained considerable traction due to their large capacity, allowing for

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

The Executive Order is relative to rescinding mandatory employee COVID vaccine or weekly testing. More information: Visit the City Manager's webpage to learn more about the current City Manager and their goals, programs, and initiatives.Informing Worcester is the City of Worcester's open data portal where interested parties can obtain public information at no cost.

COVID-19 Vaccine Bottle Market Outlook

The global COVID-19 vaccine bottle market size was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.1 billion by 2032, at a compound annual growth rate (CAGR) of 6.2%. The growth of this market can be attributed to the ongoing global vaccination efforts against COVID-19, emerging variants of the virus, and the continuous need for booster shots. The increasing demand for vaccine storage solutions and the strategic initiatives taken by pharmaceutical companies and governments worldwide are driving the market growth.

The foremost growth factor is the unparalleled global vaccination campaigns initiated to curb the spread of COVID-19. With billions of doses required worldwide, the demand for vaccine bottles has surged. Governments and international health organizations have launched massive immunization programs, leading to an unprecedented demand for safe and reliable storage solutions for vaccines. Additionally, the continuous emergence of new COVID-19 variants necessitates ongoing vaccination efforts, further propelling the market for vaccine bottles.

Another significant driver is the advancements in pharmaceutical packaging technology. Innovations in material science are leading to the development of more durable, temperature-resistant, and safer vaccine storage solutions. The demand for glass bottles remains high due to their inert nature and high resistance to thermal shock. However, the development of high-grade plastic alternatives is gaining traction, owing to their lightweight and shatterproof properties. Research and development investments in improving the efficacy and safety of vaccine packaging are expected to drive market growth over the forecast period.

Furthermore, the strategic partnerships and collaborations among pharmaceutical companies, governments, and logistics providers are enhancing the distribution efficiency of vaccines. These collaborations ensure the timely and safe delivery of vaccines to the most remote areas, thus increasing the demand for reliable packaging solutions. Investments in cold chain logistics and the establishment of robust distribution networks are pivotal factors augmenting the market growth of COVID-19 vaccine bottles.

Regionally, North America and Europe are expected to be the largest markets owing to their advanced healthcare infrastructure and significant investments in COVID-19 vaccination drives. Asia Pacific is projected to witness the fastest growth, driven by large population bases and increasing government initiatives for mass immunization. Latin America and the Middle East & Africa are also expected to show substantial growth due to improving healthcare systems and international support for vaccination programs.

Material Type Analysis

In the COVID-19 vaccine bottle market, glass remains the most preferred material type, particularly borosilicate glass, due to its non-reactive nature and high thermal stability. Glass bottles are essential in maintaining the integrity of the vaccines over a range of temperatures, making them ideal for the rigorous cold chain logistics required for COVID-19 vaccines. Despite the heavier weight and fragility of glass, its ability to ensure the vaccines' safety and efficacy makes it indispensable. Manufacturers are focusing on producing high-quality glass to meet the stringent safety standards set by health authorities.

Plastic bottles, although less prevalent than glass, are gaining traction due to their durability and lightweight properties. Advances in medical-grade plastics have led to the development of options that are shatterproof and suitable for vaccine storage. The use of plastics like cyclic olefin copolymer (COC) and cyclic olefin polymer (COP) is growing, as they offer excellent transparency, barrier properties, and chemical resistance. The demand for plastic bottles is particularly notable in regions with less stringent cold chain facilities, as they are easier to handle and transport.

The 'Others' category includes emerging materials such as eco-friendly and biodegradable options that are being researched and developed. Although still in the nascent stages, these materials are expected to gain prominence as sustainability becomes a more critical concern. The push towards reducing the environmental impact of medical waste is leading to innovations in biodegradable and recyclable materials, which could eventually capture a significant share of the market.

The competition between glass and plastic is expected to con

ObjectiveTo analyses real-world safety data of mRNA COVID-19 vaccines within the European Economic Area (EEA), using Individual Case Safety Reports (ICSR), and to evaluate the variability in safety profiles between different vaccine versions.MethodsWe utilized EudraVigilance data from 1 January 2020, to 31 December 2023, focusing on Moderna (Spikevax) and Pfizer/BioNTech (Comirnaty) vaccines against COVID-19. We performed descriptive statistics, co-occurrence analysis, and correspondence analysis to identify patterns and clusters of adverse events following immunization (AEFI).ResultsWe retrieved 993,199 ICSR (Moderna: 394,484; Pfizer: 605,794), with most reports related to women patients (69%) and non-healthcare professionals (65%). A total of 10,804 distinct AEFI terms were described across the retrieved ICSR, with a cumulative occurrence frequency of 3,558,219 (Moderna: 1,555,638; Pfizer: 2,031,828). The most prominent serious clusters included headache, fatigue, pyrexia, myalgia, arthralgia, malaise, nausea, and chills, which frequently co-occurred with vaccination failure. Specific AEFI like fever, chills, malaise, arthralgia, injection site pain, inflammation, and warmth were more often linked to Moderna, while Pfizer was more commonly associated with vaccination failure, menstrual disorders (heavy menstrual bleeding and dysmenorrhea), and hypoesthesia. In older adults, serious clusters included confusional states, cerebrovascular accidents, and myocardial infarctions, while myocarditis and pericarditis were noted in younger males. Although rare, serious systemic AEFI, like anaphylactic reactions, were identified but require further causality evaluation.ConclusionThe overall safety of mRNA COVID-19 vaccines for mass vaccination is supported, but continuous pharmacovigilance remains essential. Identified clusters of AEFI, particularly serious and systemic ones, although rare and potentially influenced by other underlying causes, underscore the need for continuous monitoring and further epidemiological investigations to explore potential causal relationships.

Univariate linear regression analysis of willingness to undergo vaccination and information source reliability.

The geometric mean titer of anti-SARS-CoV-2 RBD-IgG antibody after two doses of vaccine against COVID-19 in vaccinees with seroconversion.

Oral COVID-19 Vaccine Market Outlook

The global oral COVID-19 vaccine market size was valued at approximately $2.5 billion in 2023 and is projected to reach around $10.2 billion by 2032, expanding at a compound annual growth rate (CAGR) of 16.8% during the forecast period. This remarkable growth is driven by several factors including the increasing prevalence of COVID-19 variants, the need for easier administration methods, and the burgeoning investments in research and development for oral vaccines.

One of the primary growth factors for the oral COVID-19 vaccine market is the ongoing innovation in vaccine delivery methods. Traditional injectable vaccines pose challenges such as the need for trained healthcare professionals for administration and cold chain logistics for distribution. Oral vaccines, on the other hand, offer a convenient, non-invasive alternative that can significantly ease the logistical burdens, making immunization efforts more efficient and far-reaching. This ease of administration is particularly valuable in low-resource settings and remote areas where healthcare infrastructure may be limited.

Another significant driver is the rapid advancements in biotechnology and vaccine development technologies. New platforms such as mRNA, recombinant protein subunits, and viral vectors are being explored for developing effective oral COVID-19 vaccines. These technological advancements not only speed up the vaccine development process but also enhance the efficacy and safety profiles of the vaccines. Furthermore, continuous funding from government bodies, private sectors, and international organizations is bolstering research activities, thus propelling market growth.

The increasing awareness and acceptance of vaccines worldwide is also a crucial growth factor. Public health campaigns and government initiatives aimed at promoting vaccination are playing a critical role in boosting the uptake of COVID-19 vaccines. As more people understand the significance of vaccination in curbing the spread of the virus and preventing severe outcomes, the demand for more accessible and user-friendly vaccine options like oral vaccines is expected to rise. Additionally, the ongoing pandemic has underscored the importance of robust immunization programs, thereby reinforcing the need for innovative vaccine solutions.

The development and distribution of a Coronavirus Vaccine have been pivotal in the global fight against the pandemic. These vaccines have been instrumental in reducing the severity of COVID-19 infections and curbing transmission rates. With multiple vaccines now available, ranging from mRNA to viral vector platforms, the focus has shifted towards enhancing accessibility and addressing logistical challenges. The oral COVID-19 vaccine, in particular, represents a significant advancement in this regard, offering a more convenient and scalable solution for mass immunization. As the world continues to grapple with new variants and potential future outbreaks, the role of vaccines remains crucial in safeguarding public health and restoring normalcy.

Regionally, North America is anticipated to hold a significant share of the oral COVID-19 vaccine market due to its well-established healthcare infrastructure, high public awareness, and strong presence of key market players. Europe follows closely, driven by similar factors along with substantial government funding for vaccine research. Meanwhile, the Asia Pacific region is expected to exhibit the highest growth rate owing to its large population base, increasing healthcare investments, and growing focus on expanding immunization coverage. The Middle East & Africa and Latin America are also projected to show considerable growth, largely driven by international aid and efforts to improve healthcare accessibility.

Vaccine Type Analysis

The oral COVID-19 vaccine market is segmented by vaccine type into live attenuated, inactivated, subunit, and others. The live attenuated segment is expected to witness significant growth due to its potential to induce strong and long-lasting immunity. Live attenuated vaccines use a weakened form of the virus, which can replicate in the host without causing disease, thereby stimulating a robust immune response. These vaccines are generally more effective and require fewer doses compared to other types, making them a promising option for widespread immunization efforts.

In contrast, inactivated vaccines, which use a virus that has bee

Multivariate linear regression analysis of willingness to undergo vaccination, predictive factors.

This dataset represents preliminary estimates of cumulative U.S. RSV –associated disease burden estimates for the 2024-2025 season, including outpatient visits, hospitalizations, and deaths. Real-time estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed respiratory syncytial virus (RSV) infections. The data come from the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET), a surveillance platform that captures data from hospitals that serve about 8% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of RSV-associated disease burden estimates that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent RSV-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

Note: Preliminary burden estimates are not inclusive of data from all RSV-NET sites. Due to model limitations, sites with small sample sizes can impact estimates in unpredictable ways and are excluded for the benefit of model stability. CDC is working to address model limitations and include data from all sites in final burden estimates.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.